An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.

Autor: Ptacin JL; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA. jptacin@gmail.com., Caffaro CE; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Ma L; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., San Jose Gall KM; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Aerni HR; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Acuff NV; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Herman RW; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Pavlova Y; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Pena MJ; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Chen DB; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Koriazova LK; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Shawver LK; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Joseph IB; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA., Milla ME; Synthorx, Inc., a Sanofi Company, La Jolla, CA, USA. marcos@samsaracap.com.

Publikováno v: Nature communications [Nat Commun] 2021 Aug 09; Vol. 12 (1), pp. 4785. Date of Electronic Publication: 2021 Aug 09.